AI-generated · cited to primary sources · not investment advice
Viyash Scientific (512529) May 2025 Filing Analysis
Does management do what it says?
Transitioning the US portfolio towards complex generics. (+3 more commitments)
“Our target would be that we should double the contribution of companion animals in the next 3 years in our portfolio.”
See the full cited Management analysis of Viyash Scientific
How durable is the business?
The API business is showing signs of recovery and margin improvement, with management expecting acceleration starting from Q1 FY26. (4 expanding)
“The API business reported a revenue of INR3,378 million, reflecting a growth of 4% on a year-on-year basis.”
The India business is expanding through field force additions and new product introductions, with a second phase of expansion planned for FY26. (3 expanding, 1 stable)
“The formulations business in India... has resulted in a 13% year-on-year sales growth, which we expect to accelerate in the coming year.”
The company is shifting focus toward CDMO (Contract Development and Manufacturing) for complex generics and innovators, leveraging its R&D capabilities. (1 shifted, 1 expanding)
“Yes, absolutely. This year, that's one of the key focus, actually expanding CDMO business as well as complex products development.”
The USA segment is now specifically identified as 'USA (Human Health)' following the Viyash merger update, contributing 23% of combined Formulations revenue. It is a key pillar of the 'Sequent 3.0' strategy. (3 shifted, 1 new, 1 expanding)
“USA (Human Health) 23% of FY25 Formulations Revenue”
The API segment showed modest full-year growth of 4%, reaching ₹3,378 million. However, the latest quarter (Q4 FY25) saw a 9% decline compared to the same period last year, indicating a short-term slowdown in this segment. (1 contracting, 1 expanding)
“APIs 869 (Q4 FY25) ... 959 (Q4 FY24) ... (9%) YoY Gr%”
See the full cited Business Model analysis of Viyash Scientific
Where does growth come from?
The company is steadily optimizing its large manufacturing base, focusing on opex reduction through higher capacity utilization (currently 60-65%). (2 steady across 2 signals)
“our current capacity utilization is around 60%, 65%. When the revenue is growing, our opex percentage is continuously coming down.”
See the full cited Future Growth analysis of Viyash Scientific
What could break the thesis?
The US Human Health segment (Viyash) contributed 23% of combined formulations revenue in FY25. While overall revenue grew, the company is shifting focus toward complex generics and 'First to File' products to combat commodity pricing. (1 stable)
“New Portfolio: 10+ CGTs / NCE-1 / First to File (FTF) products. Focus on complex portfolio”
See the full cited Risk analysis of Viyash Scientific
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.